Pfizer (PFE)
27.37
+0.29 (1.07%)
NYSE · Last Trade: Oct 4th, 3:05 AM EDT
Detailed Quote
Previous Close | 27.08 |
---|---|
Open | 27.20 |
Bid | 27.33 |
Ask | 27.37 |
Day's Range | 27.04 - 27.69 |
52 Week Range | 20.92 - 30.43 |
Volume | 70,524,025 |
Market Cap | 153.46B |
PE Ratio (TTM) | 14.56 |
EPS (TTM) | 1.9 |
Dividend & Yield | 1.720 (6.28%) |
1 Month Average Volume | 58,567,894 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
The United States government is currently in the throes of a shutdown, commencing at 12:01 a.m. EDT on October 1, 2025, after a congressional impasse prevented the passage of appropriations legislation for the 2026 fiscal year. This fiscal stalemate has immediately plunged global financial markets into a state
Via MarketMinute · October 3, 2025
Gold prices have surged for an unprecedented seventh consecutive week, reaching near-record highs as of October 3, 2025. This remarkable rally, with spot gold trading between $3,859.69 and $3,885.73 per ounce and hitting an all-time peak of $3,896.49, underscores a deepening anxiety within financial
Via MarketMinute · October 3, 2025
How Trump’s 100% Tariff Threat Forced Pfizer’s Hand — Inside The High-Stakes Talks That Changed Big Pharma’s Coursestocktwits.com
Via Stocktwits · October 3, 2025
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via Benzinga · October 3, 2025
The U.S. economy finds itself at a critical juncture, navigating persistent inflation and a cooling labor market, while simultaneously grappling with the immediate and profound implications of an ongoing government shutdown. As of October 3, 2025, the federal government remains unfunded, triggering a widespread data blackout that has delayed
Via MarketMinute · October 3, 2025
Shares of scientific instrument company Bruker (NASDAQ:BRKR).
jumped 4.5% in the afternoon session after the company announced it had secured new orders worth approximately $10 million for its advanced scientific equipment from three prominent U.S. research institutions. The orders were for high-performance Nuclear Magnetic Resonance (NMR) instrumentation from the New York Structural Biology Center, the University of Delaware, and Northwestern University. Funding for these systems was supported by the National Institutes of Health (NIH) and the National Science Foundation (NSF). The equipment was intended to help research teams make breakthroughs in drug discovery and the study of diseases. This news signaled strong demand for Bruker's specialized technology from leading scientific organizations. The systems were expected to be delivered and installed in 2026.
Via StockStory · October 3, 2025
Shares of life sciences company Avantor (NYSE:AVTR)
jumped 4.9% in the afternoon session after sentiment towards the stock improved following a series of positive developments, including an analyst price target increase, a new board appointment, and the influence of an activist investor.
Via StockStory · October 3, 2025
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Friday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · October 3, 2025
London's benchmark FTSE 100 index has repeatedly scaled fresh record highs in recent days, culminating in another historic close on October 1st and continuing its upward trajectory into October 3, 2025. This impressive performance is part of a wider European market rally, signaling robust investor confidence and a pervasive "risk-on"
Via MarketMinute · October 3, 2025
Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.
Via The Motley Fool · October 3, 2025
As of October 3, 2025, the United States federal government finds itself in the throes of a significant shutdown, marking the eleventh such occurrence in modern American history and the third under President Donald Trump. The funding lapse, which began at 12:01 a.m. EDT on October 1, 2025,
Via MarketMinute · October 3, 2025
Eli Lilly and other US-based drug makers have led the market over the last few days.
Via Talk Markets · October 3, 2025
Dividend stocks can be great income-producing investments, but chasing high yields can sometimes leave you exposed to considerable risk.
Via The Motley Fool · October 3, 2025
You don't need to be rich to put your money to work on Wall Street.
Via The Motley Fool · October 3, 2025
The pharma giant just eliminated two big risks.
Via The Motley Fool · October 3, 2025
The United States economy finds itself navigating treacherous waters as a federal government shutdown grips the nation, sparking heightened concerns about widespread economic damage. What makes this particular standoff especially perilous is the accompanying delay in the release of critical economic data. As agencies responsible for tracking the nation's financial
Via MarketMinute · October 2, 2025
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Via MarketMinute · October 2, 2025
Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC. The financial institution elevated Novo Nordisk's rating from "Hold" to "Buy," triggering a robust 6.6% climb in the company's stock price.
Via MarketMinute · October 2, 2025
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
Via StockStory · October 2, 2025
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
Via StockStory · October 2, 2025
London's benchmark FTSE 100 index experienced a slight retreat on October 2, 2025, closing down 0.23% at the end of a trading day that saw it touch new record highs before succumbing to a complex mix of domestic and international pressures. This modest decline, which broke a four-day rally,
Via MarketMinute · October 2, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
Via MarketMinute · October 2, 2025
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session.
Via Chartmill · October 2, 2025